Fusing Imagination, Biomarkers and Clinical Data for Women's Propagative Potency Diagnostics Implementation

Diagnostic AI for women's reproductive health has grown mainly along single data streams: images on one side, molecular tests on the other. Uterine fibroids illustrate the pattern well. Imaging models can detect and segment lesions with high reported accuracy, while blood-based and microRNA markers describe fibroid biology but cannot locate or measure a lesion. This perspective argues that the next engineering step is a deliberately designed multimodal system in which imaging, molecular and clinical data are fused, calibrated and validated together. We describe what each modality contributes, compare fusion strategies, outline a conceptual architecture, and review the early evidence that supports fusion. We then identify the barriers (small paired datasets, missing modalities, weak external validation and deployment limits) and propose a practical roadmap. The architecture presented here is a design proposal and takes non remained empirically corroborated by the authors. Uterine fibroids are the maximum mutual benign lumps of the feminine genital tract, with prevalence usually estimated at 30-40% and up to 70-80% in predisposed groups [1]. Diagnosis rests on symptoms and imaging, and ultrasound and MRI remain the clinical gold standards, while molecular and genetic markers are expected to add earlier diagnosis and more personalized treatment [3]. The engineering problem is that each data stream is incomplete. An image tells us where a lesion is, how large it is and what it looks like, but it does not tell us what biological process produced it. A molecular marker may reflect that process, but a serum value cannot be localized, and candidate markers are still early-stage: PLP1, FOS, versican, LDH and IGF-1 have been described as promising but not as validated tests [3]. Clinical variables such as age and symptoms add risk context, yet are rarely combined with the other two in published models. A system that sees only one stream will inherit that stream's blind spots

Authors

Publication Details

Journal
International Journal of Scientific Research in Computer Science Engineering and Information Technology
Published
2026-11-15
DOI
https://doi.org/10.32628/cseit2612618
Primary Topic
Uterine Myomas and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Fusing Imagination, Biomarkers and Clinical Data for Women's Propagative Potency Diagnostics Implementation

Ravi Khatwal, Suman Shaktawat
International Journal of Scientific Research in Computer Science Engineering and Information Technology
Uterine Myomas and Treatments
article

Fusing Imagination, Biomarkers and Clinical Data for Women's Propagative Potency Diagnostics Implementation

Ravi Khatwal, Suman Shaktawat
article en

Abstract

Diagnostic AI for women's reproductive health has grown mainly along single data streams: images on one side, molecular tests on the other. Uterine fibroids illustrate the pattern well. Imaging models can detect and segment lesions with high reported accuracy, while blood-based and microRNA markers describe fibroid biology but cannot locate or measure a lesion. This perspective argues that the next engineering step is a deliberately designed multimodal system in which imaging, molecular and clinical data are fused, calibrated and validated together. We describe what each modality contributes, compare fusion strategies, outline a conceptual architecture, and review the early evidence that supports fusion. We then identify the barriers (small paired datasets, missing modalities, weak external validation and deployment limits) and propose a practical roadmap. The architecture presented here is a design proposal and takes non remained empirically corroborated by the authors. Uterine fibroids are the maximum mutual benign lumps of the feminine genital tract, with prevalence usually estimated at 30-40% and up to 70-80% in predisposed groups [1]. Diagnosis rests on symptoms and imaging, and ultrasound and MRI remain the clinical gold standards, while molecular and genetic markers are expected to add earlier diagnosis and more personalized treatment [3]. The engineering problem is that each data stream is incomplete. An image tells us where a lesion is, how large it is and what it looks like, but it does not tell us what biological process produced it. A molecular marker may reflect that process, but a serum value cannot be localized, and candidate markers are still early-stage: PLP1, FOS, versican, LDH and IGF-1 have been described as promising but not as validated tests [3]. Clinical variables such as age and symptoms add risk context, yet are rarely combined with the other two in published models. A system that sees only one stream will inherit that stream's blind spots

International Journal of Scientific Research in Computer Science Engineering and Information TechnologyVol. 12(6)
Uterine Myomas and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Fusing Imagination, Biomarkers and Clinical Data for Women's Propagative Potency Diagnostics Implementation — Ravi Khatwal, Suman Shaktawat · International Journal of Scientific Research in Computer Science Engineering and Information Technology (2026) | TGRS Research Map | TGRS